MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size is USD 184.45 Million in 2026

MEA Knee Osteoarthritis (OA) Injectable Treatments Market (By Product Type: Viscosupplements, Stem Cell Therapy Injections, Botulinum Toxin Injections, Combination Injections, Other Biologic Injections; By Mechanism of Action: Lubrication, Anti-inflammatory, and Regenerative; By Disease Severity: Mild Knee OA, Moderate Knee OA, and Severe Knee OA; By Age Group: 40–60 Years and Above 60 Years; By Duration/Dosing Frequency: Weekly over 3–5 Weeks, Multiple Dose Regimen, Single-Dose Therapy, and Monthly; By End Use: Orthopedic Clinics, Hospitals, Ambulatory Surgical Centers (ASCs), Sports Medicine Clinics, and Research Institutes / Regenerative Medicine Centers) Industry Size, Share, Growth, Trends 2025 to 2035

Report Code : 671 | Published : 12 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 17 Mn

Forecast Year,

USD 384.37 Mn

CAGR, 2026 - 2035

8.5

Report Coverage

MEA

Download Databook

The MEA knee osteoarthritis (OA) injectable treatments market size was estimated at USD 170 million in 2025 and is projected to be worth around USD 384.37 million by 2035, growing at a CAGR of 8.5% from 2026 to 2035. Growing investment in the healthcare sector and the growing elderly population are driving the market.

MEA Knee Osteoarthritis (OA) Injectable Treatments Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 170 Million
Market Size in 2026	USD 184.45 Million
Market Size by 2035	USD 384.37 Million
CAGR 2026 to 2035	8.5%
Base Year	2025
Forecast Period	2026 to 2035

The MEA knee osteoarthritis (OA) injectable treatments market is expected to grow over the forecast period, driven by an aging population, improving healthcare infrastructure, and the rising adoption of minimally invasive treatment options, such as viscosupplementation.

Expanding access to healthcare services and increasing awareness of osteoarthritis management are key factors supporting market growth. Furthermore, the increasing involvement of regional healthcare providers in international research initiatives and the gradual introduction of advanced therapies are shaping the evolving treatment landscape across the region.

Segments	Shares (%)
Viscosupplements	30%
Stem Cell Therapy Injections	25%
Botulinum Toxin Injections	10%
Combination Injections	15%
Other Biologic Injections	20%

Viscosupplements - Injectable treatments used to restore joint lubrication in knee OA patients. The viscosupplements segment held 30% share due to widespread use in treating pain and enhancing joint function.
Stem cell therapy injection - Innovative regenerative therapy targeting damaged knee cartilage for healing. The stem cell therapy injection segment held 25% share, with rising adoption driven by the promise of long-term joint repair.

Segments	Shares (%)
Lubrication	40%
Anti-inflammatory	30%
Regenerative	35%

Lubrication - Injections that restore joint fluid to improve joint mobility and lower pain. The lubrication segment held 40% share due to the most common mechanism of action for knee OA treatments and preference for minimally invasive treatments.
Regenerative - Treatments that stimulate tissue regeneration and cartilage repair in knee OA. The regenerative segment held 35% share, driven by advancements in stem cell and regenerative therapies and increasing awareness of advanced, non-surgical treatment options.

Segments	Shares (%)
Moderate Knee OA	50%
Severe Knee OA	30%
Mild Knee OA	20%

Moderate knee OA- The most common stage for injectable treatments, with moderate joint degradation. The moderate knee OA segment dominated with 50% share due to the frequent use of injectables for the management of pain and improving joint function at this stage.
Severe knee OA - Advanced stage of OA with significant joint damage. The severe knee OA segment held 30% share as severe cases typically need more invasive treatments, and the growing aging population mainly suffers from severe knee OA.

Segments	Shares (%)
40–60 Years	50%
> 60 years	40%

>60 years - Older adults with a higher prevalence of knee OA due to aging. >60 years segment dominated with 50% share due to the increased incidence of knee OA in the elderly population and expanding aging population in countries such as China, Japan, and India.
40–60 years - Middle-aged adults experiencing early to moderate OA symptoms. The 40-60 years segment held 40% share as the most affected group for knee OA treatments, as the onset often occurs in the late 40s to mid-50s.

Segments	Shares (%)
Weekly over 3–5 weeks	30%
Multiple dose regimen	35%
Single-Dose Therapy	20%
Monthly	15%

Multiple dose regimens - Multiple injections over a defined period for longer-term relief. The multiple-dose regimens segment held 35% share due to effectiveness in managing moderate knee OA and also offers more sustained, long-term pain relief.
Weekly over 3–5 weeks - Injections administered weekly to provide sustained treatment. Weekly over 3–5 weeks segment held 30% share, driven by popularity for longer-term management of knee OA symptoms.

Segments	Shares (%)
Orthopedic clinics	25%
Hospitals	40%
Ambulatory Surgical Centers (ASCs)	20%
Sports Medicine Clinics	10%
Research Institutes / Regenerative Medicine Centers	5%

Hospitals - Primary treatment centers for knee OA injectable therapies. The hospitals segment held 40% share due to their comprehensive facilities and access to a broad patient base. Hospitals provide advanced facilities, therefore preferred over other choices.
Orthopedic clinics - Specialized clinics focusing on musculoskeletal conditions, including knee OA, with high patient turnover for non-surgical knee injections. The orthopedic clinics segment held 25% share with growing adoption for targeted treatments.

Top Companies in the MEA Knee Osteoarthritis (OA) Injectable Treatments Market

Alcon, Inc.
Allergan plc
Anika Therapeutics, Inc.
Arthrex, Inc.
Bioventus, Inc.
Ferring Pharmaceuticals Inc.
Fidia Farmaceutici S.p.A.
Flexion Therapeutics, Inc.
Galderma S.A.
Hyaltech Ltd.
Landec Corporation (LifeCore Biomedical, Inc.)
Meiji Seika Pharma Ltd.
Merz Pharmaceuticals GmbH (Merz Aesthetics, Inc.)
OrthogenRx, Inc.
Roche Holding AG (F. Hoffmann-La Roche AG)
Royal Biologics
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zimmer Biomet

Segments Covered in the Report

By Product Type

Viscosupplements
Stem Cell Therapy Injections
Botulinum Toxin Injections
Combination Injections
Other Biologic Injections

By Mechanism of Action

Lubrication
Anti-inflammatory
Regenerative

By Disease Severity

Moderate Knee OA
Severe Knee OA
Mild Knee OA

By Age Group

40–60 Years
60 years

By Duration/Dosing Frequency

Weekly over 3–5 weeks
Multiple dose regimen
Single-Dose Therapy
Monthly

By End Use

Orthopedic clinics
Hospitals
Ambulatory Surgical Centers (ASCs)
Sports Medicine Clinics
Research Institutes / Regenerative Medicine Centers

List of Tables & Figures

List of Tables

Table 1: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Product Type, 2025-2035 (USD Million)
Table 2: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Mechanism of Action, 2025-2035 (USD Million)
Table 3: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Disease Severity, 2025-2035 (USD Million)
Table 4: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Age Group, 2025-2035 (USD Million)
Table 5: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Duration/Dosing Frequency, 2025-2035 (USD Million)
Table 6: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by End Use, 2025-2035 (USD Million)
Table 7: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Viscosupplements, 2025-2035 (USD Million)
Table 8: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Stem Cell Therapy Injections, 2025-2035 (USD Million)
Table 9: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Botulinum Toxin Injections, 2025-2035 (USD Million)
Table 10: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Combination Injections, 2025-2035 (USD Million)
Table 11: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Other Biologic Injections, 2025-2035 (USD Million)
Table 12: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Lubrication, 2025-2035 (USD Million)
Table 13: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Anti-inflammatory, 2025-2035 (USD Million)
Table 14: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Regenerative, 2025-2035 (USD Million)
Table 15: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Moderate Knee OA, 2025-2035 (USD Million)
Table 16: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Severe Knee OA, 2025-2035 (USD Million)
Table 17: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Mild Knee OA, 2025-2035 (USD Million)
Table 18: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by 40-60 Years, 2025-2035 (USD Million)
Table 19: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by 60 Years and Above, 2025-2035 (USD Million)
Table 20: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Weekly over 3-5 Weeks, 2025-2035 (USD Million)
Table 21: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Multiple Dose Regimen, 2025-2035 (USD Million)
Table 22: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Single-Dose Therapy, 2025-2035 (USD Million)
Table 23: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Monthly, 2025-2035 (USD Million)
Table 24: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Orthopedic Clinics, 2025-2035 (USD Million)
Table 25: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Hospitals, 2025-2035 (USD Million)
Table 26: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Ambulatory Surgical Centers (ASCs), 2025-2035 (USD Million)
Table 27: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Sports Medicine Clinics, 2025-2035 (USD Million)
Table 28: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Research Institutes / Regenerative Medicine Centers, 2025-2035 (USD Million)

List of Figures

Figure 1: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Product Type, 2025 (%)
Figure 2: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Mechanism of Action, 2025 (%)
Figure 3: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Disease Severity, 2025 (%)
Figure 4: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Age Group, 2025 (%)
Figure 5: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Duration/Dosing Frequency, 2025 (%)
Figure 6: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Share, by End Use, 2025 (%)
Figure 7: MEA Knee Osteoarthritis (OA) Injectable Treatments Market Forecast, 2025-2035 (USD Million)
Figure 8: Viscosupplements Segment Market Forecast, 2025-2035 (USD Million)
Figure 9: Stem Cell Therapy Injections Segment Market Forecast, 2025-2035 (USD Million)
Figure 10: Botulinum Toxin Injections Segment Market Forecast, 2025-2035 (USD Million)
Figure 11: Combination Injections Segment Market Forecast, 2025-2035 (USD Million)
Figure 12: Other Biologic Injections Segment Market Forecast, 2025-2035 (USD Million)
Figure 13: Lubrication Segment Market Forecast, 2025-2035 (USD Million)
Figure 14: Anti-inflammatory Segment Market Forecast, 2025-2035 (USD Million)
Figure 15: Regenerative Segment Market Forecast, 2025-2035 (USD Million)
Figure 16: Moderate Knee OA Segment Market Forecast, 2025-2035 (USD Million)
Figure 17: Severe Knee OA Segment Market Forecast, 2025-2035 (USD Million)
Figure 18: Mild Knee OA Segment Market Forecast, 2025-2035 (USD Million)
Figure 19: 40-60 Years Segment Market Forecast, 2025-2035 (USD Million)
Figure 20: 60 Years and Above Segment Market Forecast, 2025-2035 (USD Million)
Figure 21: Weekly over 3-5 Weeks Segment Market Forecast, 2025-2035 (USD Million)
Figure 22: Multiple Dose Regimen Segment Market Forecast, 2025-2035 (USD Million)
Figure 23: Single-Dose Therapy Segment Market Forecast, 2025-2035 (USD Million)
Figure 24: Monthly Segment Market Forecast, 2025-2035 (USD Million)
Figure 25: Orthopedic Clinics Segment Market Forecast, 2025-2035 (USD Million)
Figure 26: Hospitals Segment Market Forecast, 2025-2035 (USD Million)
Figure 27: Ambulatory Surgical Centers (ASCs) Segment Market Forecast, 2025-2035 (USD Million)
Figure 28: Sports Medicine Clinics Segment Market Forecast, 2025-2035 (USD Million)
Figure 29: Research Institutes / Regenerative Medicine Centers Segment Market Forecast, 2025-2035 (USD Million)

Research Methodology

Related Databooks

March 2026